Humanigen momentum barges on as Covid-19 candidate is selected for NIAID trial
One of “Pharma Bro” Martin Shkreli’s former biotechs came back from the dead during the Covid-19 pandemic thanks to its drug candidate targeting cytokine storms. Now, that company has scored itself a place in a NIAID-sponsored trial.
Humanigen $HGEN, trading for 46 cents per share as recently as mid-March, announced Monday afternoon that its lenzilumab will be tested in combination with remdesivir in NIAID’s Big Effect Trial, effectively categorizing it as a high-priority Covid-19 therapeutic candidate. The drug combo will be tested against remdesivir, a broad-spectrum antiviral that has shown in early studies to treat some symptoms of Covid-19, and a placebo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.